What are the indications for apotex's ruxolitinib?

What is Apotex’s ruxolitinib used for?

Apotex’s ruxolitinib is indicated for the treatment of:
- Myelofibrosis (MF), including primary MF and post–polycythemia vera (post-PV) or post–essential thrombocythemia (post-ET) MF, to reduce splenomegaly and disease-related symptoms in adults. [1]

- Acute graft-versus-host disease (aGVHD) in adults and children 12 years and older, after failure of one or more lines of systemic therapy. [2]

- Steroid-refractory or steroid-dependent chronic graft-versus-host disease (cGVHD) in adults and children 12 years and older who have failed one or more lines of systemic therapy. [2]

Are there age limits or line-of-therapy requirements?

Yes. For graft-versus-host disease (aGVHD and cGVHD), indications specify age 12 years and older and use after failure of prior systemic therapy. [2]

Does Apotex’s ruxolitinib cover other diseases like rheumatoid arthritis?

No. The publicly provided indications for Apotex’s ruxolitinib cover myelofibrosis and graft-versus-host disease (acute and chronic) as listed above. [1][2]

Sources

1. https://www.apotex.com/us-en/products/ruxolitinib-tablets
   
2. https://www.apotex.com/us-en/products/jakafi-ruxolitinib-tablets